Literature DB >> 6729831

Kinetics and metabolism of theobromine in male rats.

M Bonati, R Latini, B Sadurska, E Riva, F Galletti, J F Borzelleca, S M Tarka, M J Arnaud, S Garattini.   

Abstract

On the basis of general pharmacological information (blood cells/plasma partition, plasma protein binding) and using HPLC as the principal analytical method, we investigated the kinetics and metabolism of theobromine (a caffeine metabolite) in male rats after a single dose and after a 2 week chronic application. Doses in both conditions varied between 1 and 100 mg/kg. In in vitro and in vivo the fraction of theobromine unbound to plasma proteins averaged 0.90 over a wide range of concentrations. No significant difference was found in the pharmacokinetic profile of the drug after acute or chronic treatment at different doses except for a reduction in the absorption rate constant as the dose increased. AUC values increased in proportion to the dose. The 2 treatment schedules were also similar as regards metabolism, at least 50% of the administered dose of theobromine being excreted unchanged, and 25% as 6-amino-5-[N-methyl- formylamino ]1-methyluracil. Only at the highest doses was there a tendency for theobromine to accumulate at the expense of its major metabolite (a uracil compound).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6729831     DOI: 10.1016/0300-483x(84)90143-4

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  3 in total

1.  Pharmacokinetics of theobromine and its metabolites in rabbits.

Authors:  G L Traina; M Bonati
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

2.  The relevance of theobromine for the beneficial effects of cocoa consumption.

Authors:  Eva Martínez-Pinilla; Ainhoa Oñatibia-Astibia; Rafael Franco
Journal:  Front Pharmacol       Date:  2015-02-20       Impact factor: 5.810

3.  Chemical Composition and Hypotensive Effect of Campomanesia xanthocarpa.

Authors:  Liane Santariano Sant'Anna; Liara Merlugo; Catrine Santos Ehle; Jessica Limberger; Maquelen Blanco Fernandes; Marí Castro Santos; Andreas Sebastian Loureiro Mendez; Fávero Reisdorfer Paula; Cleci Menezes Moreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-11       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.